Form 4: Cytokinetics Executive Fady Ibraham Malik Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- On May 7, 2024, Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., executed a transaction involving the company's common stock.
- Malik exercised incentive stock options to acquire 14,186 shares at a price of $6.67 per share.
- Simultaneously, Malik sold 14,186 shares at $65.11 per share and an additional 1,361 shares at $65.11 per share.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on September 26, 2023.
- Following these transactions, Malik directly owns 137,056 shares of Cytokinetics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing 10b5-1 plan. There is no indication of positive or negative sentiment regarding the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any material non-public information.
Key Dates
| Date | Description |
|---|---|
| 03/23/2016 | Date the Incentive Stock Option was granted. |
| 09/26/2023 | Date the 10b5-1 plan was entered into by the Reporting Person. |
| 02/23/2026 | Expiration date of the Incentive Stock Option. |
| 05/07/2024 | Date of the transaction (exercise of options and sale of shares). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.